Synergy between μ opioid ligands:: Evidence for functional interactions among μ opioid receptor subtypes

被引:66
作者
Bolan, EA
Tallarida, RJ
Pasternak, GW
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, Lab Mol Neuropharmacol, New York, NY 10021 USA
[2] Cornell Univ, Weill Grad Sch Med Sci, Program Neurosci, New York, NY USA
[3] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19122 USA
关键词
D O I
10.1124/jpet.102.035881
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacological differences among mu opioid drugs have been observed in in vitro and in vivo preclinical models, as well as clinically, implying that all mu opioids may not be working through the same mechanism of action. Here we demonstrate analgesic synergy between L-methadone and several mu opioid ligands. Of the compounds examined, L-methadone selectively synergizes with morphine, morphine-6beta-glucuronide, codeine, and the active metabolite of heroin, 6-acetylmorphine. Morphine synergizes only with L-methadone. In analgesic assays, D-methadone was inactive alone and did not enhance morphine analgesia when the two were given together, confirming that L-methadone was not acting through N-methyl-D-aspartate mechanisms. Both L-methadone and morphine displayed only additive effects when paired with oxymorphone, oxycodone, fentanyl, alfentanyl, or meperidine. Although it displays synergy in analgesic assays, the L-methadone/morphine combination does not exhibit synergy in the gastrointestinal transit assay. This analgesic synergy of L-methadone with selective mu opioid drugs and the differences in opioid-mediated actions suggest that these drugs may be acting via different mechanisms. These findings provide further evidence for the complexity of the pharmacology of mu opioids.
引用
收藏
页码:557 / 562
页数:6
相关论文
共 53 条
[1]   Comparative immunohistochemical distributions of carboxy terminus epitopes from the mu-opioid receptor splice variants MOR-1D, MOR-1 and MOR-1C in the mouse and rat CNS [J].
Abbadie, C ;
Pan, YX ;
Drake, CT ;
Pasternak, GW .
NEUROSCIENCE, 2000, 100 (01) :141-153
[2]  
Abbadie C, 2000, J COMP NEUROL, V419, P244, DOI 10.1002/(SICI)1096-9861(20000403)419:2<244::AID-CNE8>3.0.CO
[3]  
2-R
[4]   Immunohistochemical localization of the carboxy terminus of the novel mu opioid receptor splice variant MOR-1C within the human spinal cord [J].
Abbadie, C ;
Gultekin, SH ;
Pasternak, GW .
NEUROREPORT, 2000, 11 (09) :1953-1957
[5]   Presynaptic localization of the carboxy-terminus epitopes of the μ opioid receptor splice variants MOR-1C and MOR-1D in the superficial laminae of the rat spinal cord [J].
Abbadie, C ;
Pasternak, GW ;
Aicher, SA .
NEUROSCIENCE, 2001, 106 (04) :833-842
[6]   Differential in vivo internalization of MOR-1 and MOR-1C by morphine [J].
Abbadie, C ;
Pasternak, GW .
NEUROREPORT, 2001, 12 (14) :3069-3072
[7]  
ADAMS JU, 1993, J PHARMACOL EXP THER, V266, P1261
[8]   EXPRESSION OF 2 VARIANTS OF THE HUMAN MU-OPIOID RECEPTOR MESSENGER-RNA IN SK-N-SH CELLS AND HUMAN BRAIN [J].
BARE, LA ;
MANSSON, E ;
YANG, DM .
FEBS LETTERS, 1994, 354 (02) :213-216
[9]   Methadone analgesia in morphine-insensitive CXBK mice [J].
Chang, A ;
Emmel, DW ;
Rossi, GC ;
Pasternak, GW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 351 (02) :189-191
[10]   Strategies to manage the adverse effects of oral morphine: An evidence-based report [J].
Cherny, N ;
Ripamonti, C ;
Pereira, J ;
Davis, C ;
Fallon, M ;
McQuay, H ;
Mercadante, S ;
Pasternak, G ;
Ventafridda, V .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2542-2554